###begin article-title 0
Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching
###end article-title 0
###begin p 1
###xml 33 59 33 59 <email xmlns:xlink="http://www.w3.org/1999/xlink">alt@enders.tch.harvard.edu</email>
CORRESPONDENCE Frederick W. Alt: alt@enders.tch.harvard.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 585 588 576 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 607 612 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 731 734 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 738 743 729 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 812 819 803 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 823 831 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 856 864 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 884 887 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1090 1095 1067 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1111 1114 1088 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1198 1203 1175 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1323 1328 1300 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
Nonhomologous end-joining (NHEJ) repairs DNA double-strand breaks (DSBs) during V(D)J recombination in developing lymphocytes and during immunoglobulin (Ig) heavy chain (IgH) class switch recombination (CSR) in peripheral B lymphocytes. We now show that CD21-cre-mediated deletion of the Xrcc4 NHEJ gene in p53-deficient peripheral B cells leads to recurrent surface Ig-negative B lymphomas ("CXP lymphomas"). Remarkably, CXP lymphomas arise from peripheral B cells that had attempted both receptor editing (secondary V[D]J recombination of Igkappa and Iglambda light chain genes) and IgH CSR subsequent to Xrcc4 deletion. Correspondingly, CXP tumors frequently harbored a CSR-based reciprocal chromosomal translocation that fused IgH to c-myc, as well as large chromosomal deletions or translocations involving Igkappa or Iglambda, with the latter fusing Iglambda to oncogenes or to IgH. Our findings reveal peripheral B cells that have undergone both editing and CSR and show them to be common progenitors of CXP tumors. Our studies also reveal developmental stage-specific mechanisms of c-myc activation via IgH locus translocations. Thus, Xrcc4/p53-deficient pro-B lymphomas routinely activate c-myc by gene amplification, whereas Xrcc4/p53-deficient peripheral B cell lymphomas routinely ectopically activate a single c-myc copy.
###end p 3
###begin p 4
Abbreviations used: A-EJ, alternative end-joining; AID, activation-induced cytidine deaminase; C-NHEJ, classical NHEJ; CSR, class switch recombination; DSB, double-strand break; FISH, fluorescence in situ hybridization; NHEJ, nonhomologous end-joining; QM, quasimonoclonal; RS, recombination signal sequence; SHM, somatic hypermutation; SKY, spectral karyotyping.
###end p 4
###begin p 5
J.H. Wang and C.T. Yan contributed equally to this paper.
###end p 5
###begin p 6
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 830 831 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 833 834 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 846 851 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
Ig heavy (IgH) and light (IgL) chain variable region exons are assembled from component V, D, and J segments in developing B lymphocytes. V(D)J recombination is initiated by the RAG1/2 endonuclease, which introduces DNA double-strand breaks (DSBs) between V, D, and J segments and flanking recombination signal sequences (RSs) (1). Subsequently, cleaved coding segments are joined to form V(D)J exons and RSs are joined to form RS joins (2). Both coding and RS joining are performed by classical nonhomologous end-joining (C-NHEJ), which is a major general DSB repair pathway in mammalian cells (3). Xrcc4 and DNA Ligase IV (Lig4) form a complex that is required for V(D)J recombination (4, 5). In their absence, coding or RS ends are joined at low frequency, usually with substantial sequence deletion from one or both partners (6, 7). In mice, Xrcc4 inactivation results in severe combined immune deficiency owing to inability to complete V(D)J recombination (6).
###end p 6
###begin p 7
###xml 114 117 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Igh</italic>
###xml 289 290 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 385 392 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 397 405 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 600 601 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 665 666 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 701 702 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 721 728 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 763 771 701 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 773 774 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 795 796 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 813 821 742 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 854 862 778 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 911 918 830 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1041 1042 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1208 1210 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1242 1249 1129 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1318 1326 1201 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1342 1344 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 293 297 <span type="species:ncbi:10090">Mice</span>
###xml 304 310 <span type="species:ncbi:9606">humans</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
In progenitor B (pro-B) cells in the mouse BM, productive assembly of variable region exons within the IgH locus (Igh) on chromosome 12 leads to production of IgH mu chains that signal differentiation to the precursor B (pre-B) cell stage in which IgL variable region exons are assembled (8). Mice, like humans, have two IgL families, termed Igkappa and Iglambda, which are encoded by Igkappa and Iglambda loci that, respectively, lie on chromosomes 6 and 16. Igkappa and Iglambda expression is "isotype" excluded, such that a given B cell usually expresses either Igkappa or Iglambda, but not both (9). In mice, approximately95% of mature B lymphocytes are Igkappa+, with the remainder being Iglambda+. In that context, Igkappa assembly usually precedes that of Iglambda (9). Thus, most Igkappa+ B cells contain Iglambda in germline configuration, with Iglambda rearrangements occurring in cells in which both Igkappa alleles are rearranged out-of-frame or that harbor deletions of the Jkappa segments, kappa enhancer, and/or Ckappa exons (9). Such deletions usually occur via rearrangement of Vkappas or an RS heptamer in the Jkappa-Ckappa intron (IRS) to a bona fide RS 25 kb downstream of Ckappa (3'RS) (10). Recent analyses suggest that Igkappa deletions via 3'RS rearrangements may play a role in progression to Iglambda rearrangement (11).
###end p 7
###begin p 8
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 423 430 423 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 462 469 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 516 523 508 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 542 549 530 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 577 585 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 601 603 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 604 606 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 623 624 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 706 713 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 774 775 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 839 841 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 843 845 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 879 882 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
###xml 1006 1008 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1009 1011 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1048 1049 1014 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1140 1142 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1144 1146 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 1275 1277 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1279 1281 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1360 1362 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1364 1366 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 935 940 <span type="species:ncbi:10090">mouse</span>
###xml 945 950 <span type="species:ncbi:9606">human</span>
###xml 1039 1044 <span type="species:ncbi:10090">mouse</span>
Expression of complete Ig (IgH/IgL) leads to IgM+ B lymphocytes, which ultimately down-regulate RAG expression to enforce allelic exclusion (1). However, newly generated BM IgM+ B lymphocytes that express autoreactive B cell receptors can maintain RAG expression and continue to rearrange IgL loci to generate new IgL chains in a tolerance process termed "receptor editing" (12-14). Receptor editing can replace rearranged Igkappa loci with secondary productive Igkappa rearrangements, as well as with nonfunctional Igkappa rearrangements or Igkappa deletions that may lead to Iglambda rearrangement (12-14). Thus, Iglambda+ B cells can be generated developmentally from pre-B cells with two nonproductive Igkappa rearrangements or via receptor editing from immature Igkappa+ B cells. Receptor editing is initiated in immature BM B cells (15, 16). Yet, several studies suggested IgL gene rearrangement, sometimes called "revision," in mouse and human peripheral B cells, including germinal center B cells (17-21). However, many peripheral mouse RAG+ B lineage cells are pro- or pre-B cells that migrate to the periphery after immunization (22, 23), and knock-in reporter studies suggested that although RAG genes are expressed in B cells that have just migrated from the BM (24, 25), they are not reinduced in peripheral B cells once expression is terminated (25, 26).
###end p 8
###begin p 9
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 252 253 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 313 314 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 323 325 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 467 469 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 519 521 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 583 584 567 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 732 734 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 921 923 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1111 1114 1094 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1207 1209 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
After antigen stimulation, mature IgM+ peripheral B cells can undergo IgH class switch recombination (CSR), a recombination/deletion process in which the IgH mu constant region exons (Cmu) are deleted and replaced by one of several sets of downstream CH exons (e.g., Cgamma, Cepsilon, and Calpha; referred to as CH genes) (27), leading to switching from IgM to another Ig class (e.g., IgG, IgE, or IgA). The activation-induced cytidine deaminase (AID) initiates CSR (28) by deaminating cytidines in switch (S) regions (29), which are 1-10-kb repetitive sequences located 5' of each CH gene. AID-generated lesions within the donor Smu and a downstream acceptor S region are processed into DSBs, which are end-joined to complete CSR (27). In contrast to V(D)J recombination, substantial CSR occurs in the absence of Xrcc4 or Lig4 (C-NHEJ) via an alternative end-joining (A-EJ) pathway strongly biased to use microhomology (30). However, CSR is significantly impaired in Xrcc4-deficient B cells owing to failure to join broken S regions because up to 20% of Xrcc4-deficient B cells activated for CSR in vitro have IgH chromosomal breaks, with a substantial portion participating in chromosomal translocations (30).
###end p 9
###begin p 10
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 765 768 765 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 884 889 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 1084 1087 1084 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1108 1111 1108 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
###xml 1135 1140 1135 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1161 1166 1161 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 984 989 <span type="species:ncbi:9606">human</span>
Inactivation of Xrcc4 in mice results in impaired cellular proliferation and ionizing radiation sensitivity. Xrcc4 deficiency also results in extensive apoptosis of newly generated neurons and late embryonic death (6), both of which can be rescued by deficiency for the p53 tumor suppressor (31). In this context, p53 monitors the G1 cell cycle checkpoint, signaling apoptosis of certain cell types, such as neurons and progenitor lymphocytes, which harbor persistent DSBs (32). However, as p53 deficiency does not rescue defective NHEJ associated with Xrcc4 deficiency, Xrcc4/p53-double-deficient mice are still immunodeficient and inevitably succumb to pro-B cell lymphomas that harbor RAG-dependent complex translocations (33). These translocations usually join IgH on chromosome 12 to a region downstream of c-myc on chromosome 15, resulting in dicentric 12;15 translocations and c-myc amplification via breakage-fusion-bridge cycles (34). Such complex translocations are rare in human peripheral B cell lymphomas, which more frequently harbor reciprocal translocations that fuse IgH, or less frequently IgL loci, just upstream of c-myc, leading to ectopic c-myc activation (35).
###end p 10
###begin p 11
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 195 198 195 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
In the current study, we have asked whether inactivation of C-NHEJ in WT or p53-deficient peripheral B cells leads to peripheral B cell lymphoma with CSR or V(D)J recombination-associated IgH or IgL locus translocations.
###end p 11
###begin title 12
RESULTS
###end title 12
###begin title 13
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
Inactivation of Xrcc4 in p53-deficient peripheral B cells leads to novel B cell lymphomas
###end title 13
###begin p 14
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 169 171 169 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X<sup>c</sup></italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21</italic>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 536 537 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 669 672 669 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 667 672 667 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 693 694 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 721 726 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 836 839 836 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 834 839 834 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 895 903 895 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 941 944 941 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1024 1027 1020 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 1022 1027 1018 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 1037 1039 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1121 1123 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 1136 1139 1132 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 1134 1139 1130 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 1307 1310 1303 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 1305 1310 1301 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 1362 1365 1358 1361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1366 1369 1362 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1360 1369 1356 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>&#8722;/&#8722;</sup></italic>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
###xml 1311 1315 <span type="species:ncbi:10090">mice</span>
###xml 1370 1374 <span type="species:ncbi:10090">mice</span>
We previously inactivated Xrcc4 specifically in transitional stage peripheral B cells by generating mice that harbored one copy of a loxP-flanked (floxed) Xrcc4 allele (Xc) and one copy of an Xrcc4-null allele (X-) plus a transgene that drives Cre recombinase expression via a CD21 promoter (termed CXc/- mice) (30). CD21 proteins are expressed during B cell development at the time when immature transitional B cells differentiate into mature long-lived peripheral B cells, including marginal zone B cells, follicular B cells, B1a (CD5+), and B1b cells (36). CD21cre mediates efficient Cre recombination in mature, but not immature, transitional B cells (37). Thus, CXc/- mice have normal IgM+ splenic B cell numbers as Xrcc4 is not deleted during early B cell developmental stages where V(D)J recombination occurs (30). Remarkably, CXc/- mice have a normal life span and are not cancer-prone (Fig. 1 A), despite high levels of general and IgH-specific genomic instability in ex vivo alphaCD40/IL-4-stimulated peripheral CXc/- B cells (30). Analogous to what we previously found for B lymphoid and neuronal progenitors (31), lack of CXc/- B cell transformation may reflect p53-dependent elimination of cells harboring DSBs and other types of genomic instability. To investigate this possibility, we bred CXc/- mice into a p53-deficient background to generate CXc/-P-/- mice.
###end p 14
###begin p 15
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 0 127 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Establishment of the CXP B cell lymphoma model via conditional inactivation of <italic>Xrcc4</italic> in CD21Cre-expressing, p53-deficient mice.</bold>
###xml 183 186 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 187 190 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 203 206 203 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 207 210 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 223 226 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 243 246 243 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 351 354 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 355 358 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 602 605 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 606 609 606 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
Establishment of the CXP B cell lymphoma model via conditional inactivation of Xrcc4 in CD21Cre-expressing, p53-deficient mice. (A) Kaplan-Meier survival curve: percent survival of CXc/-P-/- (n = 24); CXc/-P+/- (n = 25); CP-/- (n = 15); and CXc/- (n = 25) mice versus age in days is shown. (B) Tumor types that developed in the indicated cohorts of CXc/-P-/- and CP-/- mice. The number of mice that developed a given type of tumor is indicated at the left. Deletion of the floxed Xrcc4 allele in given tumors is indicated at the right. nd, not determined; N/A, not applicable. The asterisk indicates CXc/-P-/- mice that developed osteosarcoma or thymic lymphomas, in addition to B cell lymphomas.
###end p 15
###begin p 16
###xml 18 21 18 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 16 25 16 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>&#8722;/&#8722;</sup></italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 218 233 218 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 256 259 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 250 259 250 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>&#8722;/&#8722;</sup></italic>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 380 388 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 418 421 418 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 416 421 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CP<sup>&#8722;/&#8722;</sup></italic>
###xml 425 428 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8211;</sup>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8211;</sup></italic>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 439 442 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 433 442 433 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>+/&#8722;</sup></italic>
###xml 478 493 478 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 507 510 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 511 514 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 505 514 505 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>&#8722;/&#8722;</sup></italic>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 643 646 643 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 664 665 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 733 736 733 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 741 748 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 784 792 780 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 938 941 929 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXP</italic>
###xml 1190 1193 1176 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1188 1193 1174 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup></italic>
###xml 1240 1243 1226 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1244 1247 1230 1233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1238 1248 1224 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>c/c</sup>)</italic>
###xml 1306 1309 1292 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1310 1313 1296 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1304 1313 1290 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CX<sup>c/&#8722;</sup>P<sup>&#8722;/&#8722;</sup></italic>
###xml 1377 1379 1363 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/</sup>
###xml 1379 1380 1365 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1379 1380 1365 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>&#8722;</sup></italic>
###xml 1381 1384 1367 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1621 1626 1607 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1653 1654 1639 1640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1657 1658 1643 1644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1681 1685 1667 1671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1689 1692 1675 1678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1747 1752 1733 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1777 1780 1763 1766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1784 1788 1770 1774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1902 1907 1888 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 2259 2264 2245 2250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 2278 2285 2264 2271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
###xml 2327 2335 2313 2321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 2350 2352 2336 2338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 1194 1198 <span type="species:ncbi:10090">mice</span>
The majority of CXc/-P-/- mice become moribund by 3.5-4.5 mo of age, with >50% succumbing to Xrcc4/p53-deficient B lineage lymphomas that present predominantly in the mesenteric lymph nodes and that had deleted Xrcc4 (Fig. 1, A and B). The remaining CXc/-P-/- mice succumbed to thymic lymphomas and sarcomas characteristic of p53 deficiency alone and which had not deleted Xrcc4 (Fig. 1 B). In contrast, none of the CP-/-, CXc/-, or CXc/-P+/- littermates developed B lymphomas (Fig. 1, A and B). Of eight CXc/-P-/- B lineage lymphomas (termed CXP lymphomas) characterized in detail, all were surface Ig negative (sIg-) and all were B220+, CD43low, CD138/Syndecan-1+, and CD19+ (Fig. S1 A, available at ). In addition, all had clonal IgH and Igkappa rearrangements and many had clonal Iglambda rearrangements, even though they usually lacked expression of IgH and IgL proteins (Table S1; see below). RNA expression analyses indicated that CXP lymphomas lacked expression of lambda5 and Vpre-B, two diagnostic early B cell markers, but did show very low-level RAG expression (Fig. S1, B and C, and not depicted). We also analyzed six additional Xrcc4/p53-deficient B lymphomas derived from CXc/- mice in which the p53 gene was also floxed (CXc/-Pc/c) and found that the majority had a phenotype similar to CXc/-P-/- lymphomas (Fig. S2 and Table S2). Likewise, eight additional CXc/-P-/- B lymphomas that were also heterozygous for a mutation in the 3' IgH regulatory region (CXPR lymphomas) had a similar phenotype, including lack of surface Ig expression (unpublished data). As expected, we found little or no evidence of Xrcc4 deletion in sorted BM B220+IgM- cells or in sorted HSAhighCD21low peripheral immature B cells, but essentially complete Xrcc4 deletion in purified HSAlowCD21high mature splenic B cells (Fig. S3). By PCR, we occasionally observed very low levels of a product corresponding to Xrcc4 deletion in BM and immature B cell samples, which theoretically may reflect very low-level deletion in earlier B cell stages, but which also may simply reflect recirculating peripheral B cells in the BM and/or low-level contamination of the sorted populations (unpublished data). Along with the appearance of these B lineage tumors being dependent on Xrcc4 deletion via CD21cre expression at transitional B cell stage (Fig. 1 B and Fig. S3) (30), these phenotypic characterizations indicate that CXP lymphomas, despite lack of surface Ig expression, derive from peripheral B cells.
###end p 16
###begin title 17
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 5 12 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 18 26 14 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
IgH, Igkappa, and Iglambda rearrangements in CXP tumors
###end title 17
###begin p 18
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 338 353 334 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 433 434 429 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 444 446 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 478 479 474 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 562 563 558 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 622 623 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 630 638 626 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1037 1042 1033 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1142 1145 1138 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1648 1651 1614 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
Recurrent sIg- peripheral lymphomas have not been observed previously. To elucidate the basis for this striking phenotype, we first assayed for expression of IgH chains via Western blotting of tumor extracts. Most analyzed CXP B lymphomas lacked readily detectable IgH chain expression, although CXP62 expressed cytoplasmic gamma chains (Fig. 2, B and C). Both normal and C-NHEJ-deficient pro-B lines display rearrangements of both JH alleles (31). Assays of CXP tumor DNA for JH rearrangements via Southern blotting revealed that all primary CXP tumors showed JH rearrangements, along with varying degrees of a germline JH band (Fig. 2 A). However, the germline band usually occurred in low levels and was often further reduced in passaged tumors (unpublished data), indicating derivation from non-B lineage cells within the tumor. Despite lack of detectable IgH expression, molecular cloning demonstrated that CXP tumors contained structurally normal in-frame or out-of-frame V(D)J rearrangements, indicating that they occurred before Xrcc4 inactivation (see the following section). Finally, most CXP tumors had rearrangements in or around IgH S regions. At least five out of eight CXP tumors had clonal Smu/Cmu rearrangements; three had one or more clonal Salpha rearrangements of which one was molecularly cloned (from CXP68) and found to be an Sgamma2a to Salpha rearrangement; one CXP tumor had an Sgamma2b rearrangement; and another had a clonal Sgamma3 rearrangement in addition to the Sgamma2a to Salpha rearrangement (Table S1 and Fig. S4, A and B, available at ). Thus, most CXP tumors derived from peripheral B cells that had attempted IgH CSR.
###end p 18
###begin p 19
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CXP lymphomas harbor clonal J<sub>H</sub> rearrangements, but do not express IgM or IgL chains.</bold>
###xml 182 183 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 616 621 <span type="species:ncbi:10090">mouse</span>
CXP lymphomas harbor clonal JH rearrangements, but do not express IgM or IgL chains. (A) Southern blot analyses of CXP lymphoma genomic DNA samples for rearrangement or deletion of JH loci (representative of at least two separate analyses for each sample). (B) Western blot analyses of CXP lymphoma cellular extracts for expression of mu heavy chain and kappa or lambda light chains using HRP-conjugated anti-IgM (mu heavy chain specific), anti-kappa, or anti-lambda antibodies, respectively. (C) Western blot analyses of CXP lymphoma cellular extracts for expression of gamma heavy chains using HRP-conjugated anti-mouse IgG antibody. An alpha-tubulin antibody was used to generate a loading control in both panels. PP indicates extracts from Peyer's patches. Data presented in this figure shows results representative of two or three independent sets of analyses.
###end p 19
###begin p 20
###xml 80 88 71 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 177 184 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 319 321 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 467 475 430 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 727 728 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 744 752 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 843 851 798 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 1018 1026 973 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 1131 1133 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1222 1227 1177 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1759 1761 1702 1704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/</sup>
###xml 1761 1762 1704 1705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1761 1762 1704 1705 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>&#8722;</sup></italic>
###xml 1763 1766 1706 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1885 1892 1828 1831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1930 1937 1869 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 2131 2136 2066 2071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 2154 2161 2089 2096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
No analyzed CXP tumor expressed readily detectable Igkappa and Iglambda chains (Fig. 2 B and not depicted). Approximately 60% of normal B cells have one productively rearranged Igkappa allele and one germline allele, and approximately40% have one productive and one nonproductively rearranged or deleted Jkappa allele (38). We assayed for Jkappa rearrangements by Southern blotting and found that all eight analyzed CXP tumors lacked both copies of the Jkappa locus (Fig. 3 A and Fig. S5 A, available at ). Although there was a variable level of a germline-sized Jkappa band, the level was far below that expected for a single germline allele and roughly correlated with that of contaminating nonlymphoid DNA as judged by the JH Southern blot (Fig. 2 A). Southern blotting revealed that CXP tumors also lacked both copies of the Ckappa exons (Fig. 3 A). We tested for downstream RS rearrangement in CXP tumors via Southern blotting and found rearrangement and/or deletion of the 3'RS sequences in all analyzed tumors (Fig. 3 A and Fig. S5 A). As normal 3'RS rearrangements do not result in deletions larger than a few nucleotides (39), we tested the hypothesis that 3'RS rearrangements in CXP lymphomas had occurred after Xrcc4 inactivation by cloning and sequencing rearrangements. Of three RS rearrangements isolated, two had apparent Vkappa and 3'RS region junctions accompanied by large deletions (30-80 bp into Vkappa and 26-43 bp beyond 3'RS sequence), whereas the other had a normal Vkappa to 3'RS join (Fig. S5 B). In addition, Southern blotting with a 3'RS probe showed CXP163 had an aberrant RS rearrangement with a large deletion (>4 kb) downstream of the 3'RS sequence (Fig. S5 C). Southern blotting also showed that a significant proportion of CXc/-Pc/c B lymphomas (four out of six; Fig. S2) and CXPR B lymphomas (five out of eight; not depicted) had deleted one or both Igkappa alleles. We conclude that deletional Igkappa 3'RS rearrangements in CXP tumors are reminiscent of those associated with attempted V(D)J joining in the absence of C-NHEJ, suggesting they occurred in progenitors of CXP tumors subsequent to Xrcc4 inactivation via CD21cre expression.
###end p 20
###begin p 21
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Aberrant IgL rearrangements in CXP lymphomas.</bold>
Aberrant IgL rearrangements in CXP lymphomas. (A, right) Southern blot analyses for Jkappa rearrangements in CXP lymphoma genomic DNA using BamHI digestion and the 3' Jkappa and Ckappa probes indicated in schematic at top of panel. (left) Southern blot analysis for RS rearrangements in CXP lymphoma DNA using BglII digestion and the indicated RS0.8 probe. Germline (GL) bands and their known sizes are indicated (arrows). Blots were performed at least two times. (B) Assays for rearrangements occurring in or near Vlambda and Jlambda segments in DNA samples from CXP lymphomas. Rearrangements were isolated either by PCR or by cloning from lambda-phage genomic DNA libraries generated from individual tumor DNA samples. Black arrows denote the position of the PCR primers used for the studies, and primer sequences are indicated in the Materials and methods section. The two breakpoints for a given rearrangement in the vicinity of Vlambda and Jlambda in a particular tumor are indicated by the same number with the breakpoint in the Jlambda region indicated by a (') symbol. PCR analyses were performed at least three times from one or multiple independent DNA samples from a given tumor. PCR fragments were subcloned into the pGEM vector, and 10-20 subclones were sequenced. Identical rearrangements that were isolated from >80% of the subclones were scored as clonal rearrangements. At least two independent phage clones were isolated from each genomic library and the junctions found in phage clones were independently confirmed as clonal junctions in a given tumor by PCR analyses of tumor cell DNA. Sequences of cloned Vlambda and Jlambda rearrangement junctions are shown in Fig. S5E.
###end p 21
###begin p 22
###xml 9 16 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 88 89 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 99 101 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 334 336 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/</sup>
###xml 336 337 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 336 337 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>&#8722;</sup></italic>
###xml 338 341 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 373 381 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 564 572 535 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 639 647 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 843 851 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 888 896 824 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1174 1182 1085 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1199 1201 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1294 1302 1205 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1587 1595 1459 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1645 1653 1517 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1953 1954 1820 1821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 1956 1958 1823 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 2027 2035 1894 1897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 2064 2069 1926 1931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 2083 2090 1945 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Complete Igkappa deletion is generally observed in a subset of mouse peripheral Iglambda+ B cells (39). Therefore, we assayed CXP lymphoma DNA by Southern blotting with probes to detect VlambdaJlambda rearrangements within both Iglambda clusters (Fig. S5 D). These analyses demonstrated that at least six out of nine assayed CXP or CXc/-Pc/c B cell lymphomas had clear-cut Iglambda rearrangements, with CXP62, 162, and 163 showing rearrangements of both alleles (Fig. S5, A and D). Southern blotting analyses also showed that several analyzed CXPR B lymphomas had Iglambda rearrangements (unpublished data). To elucidate the nature of the Iglambda rearrangements in CXP tumors, we performed PCR using Vlambda1/Vlambda2- and Jlambda1/Jlambda2-specific primers to isolate six different rearrangements involving one or the other Jlambda cluster (Fig. 3 B and Fig. S5 E). Nearly all isolated Iglambda rearrangements involved joining of sequences in or upstream of a Vlambda to sequences in or downstream of a Jlambda, with the majority of breakpoints leading to deletions larger than the few basepair deletions observed from one or both segments in normal VlambdaJlambda joins (Fig. 3 B and Fig. S5 E) (40). As PCR only allows isolation of junctions within the primer boundaries, we cloned several Iglambda rearrangements from genomic phage libraries generated from CXP163 and CXP162 DNA and identified a deletional rearrangement that went approximately2.8-kb and approximately800-bp, respectively, beyond the Vlambda1 and Jlambda1 segments, as well as aberrantly deleted RS rearrangements (Fig. 3 B and Fig. S5 E). Overall, the observed pattern of Iglambda rearrangements in CXP lymphomas, namely large deletions from the participating segments on one or both sides of the join, is fully consistent with the types of junctions previously characterized for attempted V(D)J recombination of endogenous loci in C-NHEJ-deficient progenitor B or T lymphocytes (3, 41). Therefore, CXP tumors appear to arise from B cells that attempted Iglambda rearrangement subsequent to Xrcc4 deletion via CD21cre expression.
###end p 22
###begin title 23
###xml 63 66 63 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
C-NHEJ suppresses oncogenic CSR-related translocations between IgH and c-myc
###end title 23
###begin p 24
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 435 443 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 622 623 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 628 631 628 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 794 795 794 795 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 808 811 808 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 959 967 959 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 1042 1045 1042 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1050 1055 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1200 1205 1200 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1210 1213 1210 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1300 1303 1300 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1304 1307 1304 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1429 1432 1429 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1437 1442 1437 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
Spectral karyotyping (SKY) revealed that six out of eight characterized CXP tumors (CXP68, 153, 162, 163, 221, and 2152) harbored clonal translocations between chromosomes 12 and 15, possibly involving IgH (Chr12) and c-myc (Chr15) loci (Fig. 4 A, Table S3, and Fig. S6 A, available at ). To test this possibility, we performed fluorescence in situ hybridization (FISH) with 5' and 3' IgH BAC probes plus a BAC probe containing c-myc (Fig. 4 A). These analyses demonstrated that 5 out of 6 tumors (CXP68, 153, 162, 163, and 2152) harbored reciprocal t(12;15) and t(15;12) translocations in which the centromeric portion (CH) of IgH (3' IgH probe) was fused proximal to the telomeric portion of Chr15 in or around c-myc (c-myc BAC probe) to yield the t(12;15) translocation, and the telomeric (VH) portion of IgH (5' IgH probe) was fused proximal to the centromeric portion of Chr15 in or just upstream of c-myc to yield the reciprocal t(15;12) translocation (Fig. 4 A and Fig. S6 A). CXP221 harbored a clonal t(12;15) translocation involving IgH and c-myc loc, but lacked the reciprocal t(15;12) translocation, and instead contained a clonal t(15;7) translocation (Fig. S6 A). Based on FISH, neither c-myc nor IgH appeared amplified in CXP tumors. Similar to CXP tumors, three out of four analyzed CXc/-Pc/c B lymphomas and six out of six CXPR tumors analyzed had translocations involving chromosomes 12 and 15 that involved the IgH and c-myc loci (Fig. S6 A, Table S4, and not depicted).
###end p 24
###begin p 25
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reciprocal <italic>IgH/c-myc</italic> translocations in CXP lymphoma.</bold>
###xml 128 137 128 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 177 183 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242; IgH</italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 394 397 394 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 697 706 697 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
Reciprocal IgH/c-myc translocations in CXP lymphoma. (A) SKY, FISH, and chromosome paint analyses (Chr12 pink, Chr15 green) for IgH/c-myc translocations in CXP163 and CXP153. A 3' IgH BAC (light green) and a c-myc BAC (light green) were used in combination with chromosome paints to detect t(12;15) translocations. The t(15;12) translocation, not detectable by SKY, was visualized using the 5' IgH BAC (pink) and a Chr15 paint (green). At least 15 metaphase spreads were analyzed for SKY, FISH, and chromosomal paints, respectively, for each CXP tumor. Translocations shown were observed in the majority of metaphases, and were scored as clonal if observed in >80% of metaphases. (B) Schematic of IgH/c-myc translocation breakpoint junctions cloned and sequenced from lambda-phage tumor genomic DNA libraries. At least two independent phage clones were isolated from each genomic DNA library, and breakpoint junctions identified within them were further independently confirmed by PCR and sequencing from the appropriate tumor DNA samples. The numbers on the top indicate t(12;15) translocation breakpoints and the same numbers containing a (') on the bottom indicate the "reciprocal" t(15;12) translocation breakpoints in the corresponding tumor: CXP153 (junction 1 and 1'), 163 (junction 2 and 2'), and 68 (junction 3').
###end p 25
###begin p 26
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 560 565 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 799 804 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 915 920 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 928 936 928 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 937 942 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1042 1047 1037 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-myc</italic>
###xml 1195 1197 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1237 1240 1232 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
To further analyze CXP B lymphoma t(12;15) and t(15;12) translocation junctions, we performed Southern blotting with probes within or just upstream of c-myc (Fig. S6 B). These analyses demonstrated that the six CXP lymphomas with t(12;15) translocations had clonal rearrangements in or around c-myc (Fig. S6 B and not depicted), with one additional tumor that lacks a t(12;15) translocation (CXP62; detailed in the following section), also showing a clonal c-myc rearrangement (Fig. S6 B). Southern blotting confirmed that none of the CXP tumors had amplified c-myc (Fig. S6 B). Northern blotting with a c-myc probe further demonstrated that all CXP tumors with t(12;15) translocations had greatly increased c-myc expression, indicating ectopic overexpression from a single copy of the translocated c-myc gene (Fig. S6 C). Of note, only two CXP tumors lacked t(12;15) translocations; however, one (CXP62) activated c-myc via an Iglambda/c-myc translocation (see below) and the other (CXP35) had a complex Chr12 translocation that resulted in N-myc amplification and overexpression (Fig. S6 C and Fig. S7 A, available at ) reminiscent of that observed in Artemis/p53-deficient pro-B cell tumors (42). Thus, all CXP tumors overexpressed a myc family gene.
###end p 26
###begin p 27
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 284 292 284 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 333 341 333 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 591 596 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 687 692 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 694 702 689 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 792 797 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 849 851 843 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H3</sub>
###xml 857 859 851 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H4</sub>
###xml 892 897 886 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 906 914 900 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1009 1010 1003 1004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1014 1015 1008 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1031 1039 1025 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 1318 1323 1306 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1332 1340 1320 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1514 1517 1498 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1518 1523 1502 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1618 1621 1602 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1644 1649 1628 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1574 1579 <span type="species:ncbi:9606">human</span>
To further elucidate IgH/c-myc translocations in CXP tumors, we isolated translocation junctions by screening genomic DNA libraries from individual tumors. Nucleotide sequence analyses showed that all five characterized junctions corresponded to translocations between IgH and c-myc (Fig. 4 B and Fig. S6 D). All junctions on Chr12 (Fig. 4 B, red), including those associated with both t(12;15) and t(15;12) occurred within IgH, most in the CH region within or around S regions consistent with derivation via aberrant CSR. The CXP153 t(12;15) junction linked Sgamma1 to sequences just 5' of c-myc (junction 1, CXP153), whereas the t(15;12) linked Smu to sequences in the first intron of c-myc (Fig. 4 B and Fig. S6 D). The CXP163 t(12;15) junction linked Imu to a sequence 288 bp upstream of c-myc exon 1, and the t(15;12) linked sequences between JH3 and JH4 to sequences 289 bp upstream of c-myc exon 1 (Fig. 4 B and Fig. S6 D); notably, the CXP163 t(15;12) junction occurred downstream of a nonproductive VH(D)JH rearrangement (Fig. 5 B), indicating that it did not happen during V(D)J recombination and, rather, may have resulted in association with a large deletion from a breakpoint downstream in Imu-Smu region. Finally, the t(15;12) CXP68 junction linked sequences near Igamma3 to sequences 1.4-kb upstream of c-myc exon 1 (Fig. 4 B), again, likely resulting from attempted CSR to Sgamma3. Four of these five cloned junctions contained junctional microhomology suggestive of A-EJ (Fig. S6 D). Overall, CXP IgH/c-myc translocations are remarkably similar to those of human sporadic Burkitt's lymphoma that fuse IgH S regions upstream of c-myc.
###end p 27
###begin p 28
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 92 93 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 205 206 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 291 300 291 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 371 372 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 376 377 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 493 494 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 515 526 515 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A&#8211;C</xref>
###xml 569 570 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 574 575 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 717 718 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 722 723 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 766 769 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 809 810 809 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 814 815 814 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 984 985 984 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 989 990 989 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1058 1069 1058 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A&#8211;D</xref>
###xml 1171 1174 1171 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
Because of the location of the characterized translocation junctions downstream of the IgH JH region, we considered the possibility that many CXP tumors were sIg- because they separated a productive VH(D)JH exon from the CH region. In this context, two out of three analyzed CXP tumors with IgH/c-myc translocations (CXP68 and CXP153) contained an in-frame (productive) VH(D)JH rearrangement fused to the c-myc locus on Chr15; whereas the other (CXP163) involved a translocated nonproductive VH(D)JH rearrangement (Fig. 5, A-C). In CXP163, which has the nonproductive VH(D)JH translocated to c-myc, the other Chr12 was involved in a t(12;16) translocation that may have resulted in loss of the presumably productive VH(D)JH exon, as the breakpoint is centromeric to IgH (Fig. 7 A and Fig. S7 A). Of the four VH(D)JH junctions and downstream flanks sequenced (3,884 bp), one carried two somatic point mutations and the other three lacked mutations (unpublished data). Finally, cloned VH(D)JH rearrangements appeared normal in respect to junctional deletions (Fig. 5, A-D), indicating they occurred in C-NHEJ-proficient cells. Therefore, primary V(D)J recombination at the IgH locus was normal in B lineage cells that gave rise to CXP lymphomas.
###end p 28
###begin p 29
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CXP lymphomas harbor normal V(D)J rearrangements in IgH locus.</bold>
###xml 104 105 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 412 417 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 513 518 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
CXP lymphomas harbor normal V(D)J rearrangements in IgH locus. Nucleotide sequence analysis of primary VH(D)JH rearrangements cloned from the following: CXP153 by both lambda-phage library and PCR (A); CXP163 by lambda-phage library (B); CXP68 by PCR (C); and CXP2152 by PCR (D). Additional sequence analyses revealed that CXP153 had a productive V7183-D-JH2 rearrangement juxtaposed into to the first intron of c-myc and CXP163 has a nonproductive VH12-D-JH2 rearrangement juxtaposed to the sequence upstream of c-myc exon1. V regions are shown in blue and J regions in red. The open reading frame is indicated under the DNA sequence. PCR analyses were performed at least three times from one or multiple independent tumor DNA samples. PCR fragments were subcloned into pGEM vector, 10-20 subclones were sequenced, and identical rearrangements observed in >80% clones were scored as clonal rearrangements.
###end p 29
###begin title 30
###xml 32 40 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
CXP lymphomas frequently harbor Iglambda translocations
###end title 30
###begin p 31
###xml 327 335 327 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 474 482 474 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 534 537 534 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 605 613 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 691 699 686 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 758 766 748 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 768 776 753 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 800 808 785 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 825 833 805 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 863 871 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 974 982 944 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 984 992 949 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 1072 1079 1037 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1143 1146 1104 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1147 1150 1108 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1216 1219 1177 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1220 1223 1181 1184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1280 1288 1241 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1387 1394 1343 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1417 1424 1369 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
SKY analyses demonstrated that five out of eight characterized CXP B lymphomas (CXP35, 62, 68, 162, and 163), many of the same ones that harbored translocations between chromosomes 12 and 15, harbored Chr16 translocations to various other chromosomes with two others (CXP153 and 2152) harboring nonclonal Chr16 translocations (Fig. 6 A, Table S3, and Fig. S7 A). In contrast to the Chr12 translocations, all but one Chr16 translocation (i.e., CXP62) appeared nonreciprocal (Fig. 6 A and Fig. S7 A), similar to RAG-initiated oncogenic IgH translocations in Xrcc4/p53-deficient pro-B lymphomas (34). As the Iglambda locus is on Chr16, we used FISH with three different BAC probes covering the Iglambda locus to determine whether the Chr16 breakpoints involved Iglambda (Fig. 6 A; P12 is centromeric to Iglambda, E14 spans both Iglambda clusters, P9 is telomeric to Iglambda). These analyses revealed that all five Chr16 breakpoints occurred directly within various regions of Iglambda (Fig. 6 A and Fig. S7 A). We also observed clonal translocations of Chr6 (which contains Igkappa) in one of eight CXP tumors and in two of four characterized CXc/-Pc/c B lymphomas (Tables S3 and S4). Notably two tumors (CXP162 and CXc/-Pc/c 1893) harbored clonal t(6;16) translocations that fused Iglambda to Chr6. However, cytogenetic analyses indicated that these t(6;16) translocations did not harbor Igkappa (Fig. S7 A), although Igkappa may still have been involved and deleted during joining (see the following section).
###end p 31
###begin p 32
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Recurrent chromosome 16 translocations.</bold>
###xml 65 73 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 133 141 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 526 534 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 622 630 607 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 637 643 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242; IgH</italic>
###xml 655 657 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P9</italic>
###xml 1448 1453 1414 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1482 1490 1443 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
Recurrent chromosome 16 translocations. (A) SKY/FISH analyses of Iglambda translocations in CXP lymphomas. (A, top) schematic map of Iglambda locus in germline configuration and the location of the three BACs used for FISH (P9, E14, and P12).(bottom) SKY revealed a t(12;16) translocation in CXP68, and a reciprocal t(16;15) and t(15;16) translocation in CXP62. FISH and chromosome paints (Chr12 pink, Chr16 light blue or white, Chr15 green) showed the breakpoints of Chr16 translocations occurred in different regions of the Iglambda locus, indicated by yellow lightning symbols over metaphases hybridized with different Iglambda BACs. 3' IgH (pink) and P9 (light blue) BACs were colocalized at the junction of t(12;16) in CXP68. CXP62 has a reciprocal translocation with P12 BAC (white) on the der(16)t(16;15) and E14 and P9 (white) BACs on the der(15)t(15;16). At least 15 metaphase spreads were analyzed for each of the cytogenetic analyses, and representative clonal translocations observed in >80% of the metaphases are shown. (B, top) Cloning of t(12;16) breakpoints from a genomic library made from CXP68 DNA. Nucleotide sequence analyses of cloned junction (shown in Fig. S7 B) indicated breakpoints occurred between Cdelta in IgH and Jlambda2 in Iglambda locus. (bottom) Cloning of t(16; 15) breakpoints from a genomic library made from CXP62 DNA. Nucleotide sequence analyses indicated breakpoints occurred between sequences upstream of c-myc exon 1 and Jlambda1 with 3' Iglambda enhancer in close proximity. At least two independent phage clones were isolated from each genomic library and the junctions found in phage clones were independently confirmed as clonal junctions in a given tumor by PCR analyses of tumor DNA sample. Fig. S7 is available at .
###end p 32
###begin p 33
###xml 28 36 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 297 301 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-</italic>
###xml 319 322 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 418 426 413 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 514 522 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 612 620 597 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 745 750 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 759 767 739 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 822 827 802 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1001 1006 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-myc</italic>
###xml 1061 1069 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1074 1077 1049 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1200 1203 1175 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1208 1216 1183 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1248 1256 1218 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 1321 1324 1287 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1352 1360 1313 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1362 1370 1318 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
Characterization of several Iglambda breakpoints by FISH and/or molecular cloning revealed partner loci and showed that sequences around translocation junctions lacked somatic hypermutation (SHM; Fig. S7 B and not depicted). By SKY, the CXP62 tumor, which was the only one that did not activate a myc-family gene by an IgH translocation, contained reciprocal t(16;15) and t(15;16) translocations, which juxtaposed the Iglambda P12 BAC probe to the telomeric portion of Chr15 in the t(16;15) translocation, and the Iglambda P9 and E14 BAC probes to the centromeric portion of Chr15 in the t(15;16) translocation (Fig. 6 A). Based on analyses of cloned junctions, the t(16;15) translocation fused sequences upstream of Jlambda1 to sequences 5' of c-myc exon 1 (Fig. 6 B and Fig. S7 B), which led to high level expression of c-myc transcripts (Fig. S6 C), whereas the t(15;16) translocation contained the reciprocal product (Fig. S7 B). FISH analyses of the complex t(12;12;16) translocation that led to N-myc amplification in CXP35 revealed that it involved both Iglambda and IgH loci (Fig. S7 A). Likewise, FISH analyses of the nonreciprocal t(12;16) CXP68 translocation revealed colocalization of 3' IgH and Iglambda P9 BAC probes at the junction (Fig. 6 A). By phage cloning, we mapped the CXP68 breakpoint to Cdelta in IgH and just 3' of Jlambda2 in Iglambda (Fig. 6 B and Fig. S7 B).
###end p 33
###begin title 34
Comparative genomic hybridization analyses of CXP tumors
###end title 34
###begin p 35
###xml 184 187 184 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 342 349 342 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 550 557 546 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 620 627 612 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 652 655 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 656 659 644 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 924 931 912 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
We used comparative genomic hybridization (CGH) to assay for sequence copy number differences among tumor and control tissues samples. Among the four samples derived from the CXP or CXc/-Pc/c cohort, three had clearly lost one copy of either the entire Chr6 or a large region of Chr6, with the boundary of the loss occurring near or spanning Igkappa (Fig. S8, available at , and not depicted). Out of nine CXPR B lymphoma DNAs analyzed, seven again had a clear loss of one copy of the entire Chr6 or a large region that in two extended directly from Igkappa (Fig. S8 and not depicted). CGH also showed focal deletion of Igkappa in most analyzed CXP, CXc/-Pc/c, or CXPR tumors (Fig. S8 and not depicted), which is consistent with results of Southern blotting analyses. In contrast, three thymic lymphomas and two forebrain tumors, most likely of glial origin, analyzed did not show loss of Chr6 or a large region proximal to Igkappa (Fig. S8 and not depicted).
###end p 35
###begin title 36
DISCUSSION
###end title 36
###begin p 37
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 196 198 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 306 309 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 430 433 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 448 455 436 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
###xml 468 473 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 582 583 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 618 621 606 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 704 709 692 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 779 781 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 783 785 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 787 789 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 905 908 893 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1031 1036 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1160 1163 1148 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1168 1171 1156 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
###xml 1199 1202 1187 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1207 1210 1195 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgL</italic>
###xml 1395 1398 1383 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1403 1411 1391 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
Xrcc4 deficiency in peripheral B cells does not predispose to B cell lymphoma, despite dramatic IgH instability in Xrcc4-deficient B cells activated for CSR by treatment with alphaCD40 plus IL-4 (30). In this context, alphaCD40 plus IL-4-activated splenic CXP B cells had at most a very modest increase in IgH breaks compared with activated Xrcc4-deficient peripheral B cells (28 +/- 13% versus 17 +/- 7% of metaphases containing IgH breaks). Yet, CD21cre deletion of Xrcc4 in p53-deficient peripheral B cells, or deletion of both genes in peripheral B cells, recurrently led to sIg- B lymphomas that harbor activated myc, likely reflecting the critical role of p53 in eliminating B cells with activated c-myc expression and/or eliminating B cells with high genomic instability (33, 43, 44). CXP B lymphomas are remarkable in several ways. First, most CXP lymphomas arise from B cells that have attempted IgH CSR and a majority appear to arise from B cells that have undergone receptor editing, with both processes occurring after Xrcc4 inactivation by CD21Cre. Second, many CXP tumors harbored two separate, clonal translocations that, respectively, involved IgH and IgL loci. Occurrence of clonal IgH and IgL translocations in the same tumor may reflect dual CSR and editing activities of B cells from which they arose. In this context, some CXP lymphomas had clonal translocations that fused IgH and Iglambda, clearly indicating simultaneous presence of breaks in both loci in tumor progenitors. As outlined below, these unusual features of CXP tumors have novel implications for B cell developmental processes and for oncogenic translocation mechanisms.
###end p 37
###begin p 38
###xml 113 114 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc,</italic>
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 204 207 204 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 475 478 475 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 627 630 627 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 631 636 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 723 726 723 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 727 732 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 768 771 768 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 808 809 808 809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 813 814 813 814 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 882 885 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1043 1052 1043 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 1139 1142 1139 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1189 1194 1189 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1225 1234 1225 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 1372 1375 1372 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1383 1388 1383 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1467 1472 1467 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1528 1531 1528 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1536 1541 1536 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1591 1596 1591 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 1754 1763 1754 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 1949 1958 1949 1958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 503 508 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
Germline Xrcc4 plus p53 deficiency in mice leads to pro-B lymphomas with RAG-dependent translocations that fuse JH sequences to sequences far downstream of c-myc, resulting in dicentric chromosomes and c-myc activation via breakage-fusion-bridge amplification (34). Thus, it is remarkable that inactivation of same two genes in mature B cells recurrently leads to ectopic activation of a single copy c-myc gene by fusion of IgH into its upstream region, analogous to similar IgH/c-myc translocations in human Burkitt's lymphoma and diffuse large B cell lymphomas (35). In pristane- or IL-6-induced mouse plasmacytomas, similar IgH/c-myc translocations occur and are initiated by AID (45, 46). In this context, CXP lymphoma IgH/c-myc translocations occur in and around IgH S regions and downstream of normal VH(D)JH exons, indicating their likely selection from the abundant pool of IgH translocations that result from aberrant CSR in activated Xrcc4-deficient peripheral B cells (30). As the intronic IgH enhancer is generally absent from CXP IgH/c-myc translocations, long-range 3' IgH regulatory region activity (47), or that of unknown IgH regulatory elements, may ectopically activate c-myc. The recurrent differences in IgH/c-myc translocations in Xrcc4/p53-deficient pro-B versus CXP peripheral B cell tumors might reflect RAG versus AID-dependent DSB initiation in IgH and/or c-myc, other differential stage-specific mechanisms that lead to DSBs in and around c-myc, stage-specific differences in nuclear localization of IgH and c-myc loci, or mechanisms that differentially activate c-myc after translocation, including stage-specific IgH enhancer activities. As both Xrcc4/p53-deficient pro-B and CXP peripheral B cell lymphomas frequently have IgH/c-myc junctions that appear to be mediated by A-EJ, repair pathway choice is not likely to be a major factor in generating a particular form of translocation. Given the uniform and recurrent IgH/c-myc translocations, the CXP B lymphoma system should allow putative roles of cis elements and other factors to be tested.
###end p 38
###begin p 39
###xml 111 119 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 126 131 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 159 167 154 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 308 316 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 347 352 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 375 380 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 408 422 393 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;/c-myc</italic>
###xml 477 479 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 517 525 497 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 723 730 698 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 783 790 754 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 966 968 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 458 463 <span type="species:ncbi:9606">human</span>
###xml 959 964 <span type="species:ncbi:4932">yeast</span>
CXP lymphomas also frequently harbor chromosome 16 translocations that involve aberrant V(D)J recombination of Iglambda after Xrcc4 deletion. At least one CXP Iglambda translocation was oncogenic. CXP62 had reciprocal t(15;16) and t(16;15) translocations, the latter of which fused the downstream portion of Iglambda to sequences just upstream of c-myc, resulting in ectopic c-myc activation, reminiscent of Iglambda/c-myc translocations observed in certain human B lymphomas (35). Characterization of additional CXP Iglambda translocations may lead to identification of additional oncogenes. Notably, we also observe loss of all or part of one copy of chromosome 6 with some large deletions extending from the vicinity of Igkappa. The latter findings suggest that rearrangements of Igkappa, likely in association with aberrant editing, may also lead to translocations or chromosome loss. In the latter context, unrepaired DSBs can lead to chromosome loss in yeast (48). The frequent loss of all or a large portion of chromosome 6 in CXP tumors is striking and suggests a potential role in etiology of these tumors, perhaps by deletion of a tumor suppressor sequence.
###end p 39
###begin p 40
###xml 119 126 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 139 147 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 175 176 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 248 255 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 346 348 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 350 352 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 461 468 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 502 504 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 569 576 530 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 736 743 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
###xml 917 922 856 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1024 1031 963 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1051 1059 986 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 384 389 <span type="species:ncbi:10090">mouse</span>
More than 95% of mouse peripheral B cells express Igkappa and, correspondingly, have VkappaJkappa joins on one or both Igkappa alleles and Iglambda in germline configuration (9). A small percentage of mouse B cells express Iglambda, and these have Igkappa alleles that are nonproductively rearranged or deleted by 3'RS or related rearrangements (39, 49). Notably, Iglambda-expressing mouse B cells frequently arise via receptor editing, often in the context of Igkappa deletion via 3'RS rearrangement (39). Thus, it is striking that CXP lymphomas frequently had clonal Igkappa deletions via aberrant Vkappa to 3'RS rearrangements and aberrant Vlambda to Jlambda rearrangements, with both types of rearrangements occurring subsequent to CD21cre expression. Based on these findings, we speculate that a common CXP tumor progenitor derives from an Igkappa-expressing B cell that attempted receptor editing subsequent to Xrcc4 deletion. Attempted editing in the absence of Xrcc4 would lead to aberrant rearrangement/deletion of Igkappa and progression to Iglambda rearrangement, which also would be aberrant. Thus, editing Xrcc4-deficient B cells would lose IgL expression caused by inability to undergo productive IgL editing.
###end p 40
###begin p 41
###xml 216 224 216 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 293 296 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 313 315 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 328 337 323 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 446 460 441 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;/c-myc</italic>
###xml 475 484 465 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 666 674 656 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 730 738 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 759 762 739 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 789 792 769 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 855 858 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
As a working model, we suggest that aberrant receptor editing in CXP tumor progenitors generates an initial transforming event and/or activates aberrant CSR through loss of parts of chromosome 6 or translocations of Iglambda. Aberrant CSR in the absence of Xrcc4 would lead to a high level of IgH translocations (30), including IgH/c-myc translocations that would complete the transformation process. In the case of the CXP tumor that harbors an Iglambda/c-myc instead of an IgH/c-myc translocation, the former may have been sufficient to fully transform the cells. This scenario provides a potential role for chromosome 6 losses, and also could explain why all CXP Iglambda translocations are not clearly oncogenic, why some CXP Iglambda translocations have IgH as a partner, and why CXP IgH translocations can involve either productive or nonproductive IgH alleles.
###end p 41
###begin p 42
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 203 211 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 255 258 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 362 364 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 474 476 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 645 647 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 919 924 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1109 1116 1095 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 1121 1129 1103 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1157 1160 1134 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1256 1264 1233 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1461 1464 1433 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1532 1534 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 1536 1538 1508 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 1572 1575 1544 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 1611 1614 1578 1581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1615 1618 1582 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1639 1642 1606 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 1647 1652 1614 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 1904 1906 1871 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
Receptor editing is generally thought to occur in immature B cells in the BM (16); yet a substantial fraction of CXP tumor progenitors appear to have both breaks associated with attempted editing of the Iglambda locus and breaks associated with attempted IgH CSR. In this regard, BM immature B cells in quasimonoclonal (QM) mice can express both AID and RAG1/2 (50), although other studies of developing B cells in WT mice concluded that AID is not expressed in BM B cells (51). QM mice harbor a productive IgH knock-in V(D)J allele and a homozygous gene-targeted deletion of both Jkappa alleles and, thus, only have Iglambda-producing B cells (52). The striking similarities between immature QM B cells and proposed CXP tumor progenitors suggest a potential relationship. In this regard, CXP tumor progenitors might derive from an undetected, low-level population of CD21cre-expressing BM immature B cells that delete Xrcc4 and undergo aberrant editing and CSR before migration to the periphery. However, we note that CXP tumors arise in the periphery, have features of peripheral B cells, and harbor clonal Igkappa and Iglambda rearrangements, as well as IgH CSR-associated rearrangements that occurred subsequent to CD21cre expression. Conceivably, the Iglambda breaks that lead to translocations found in CXP tumor progenitors might reflect RAG-initiated breaks in BM developing B cells that persist because of p53 deficiency, as observed for RAG-initiated IgH breaks in ATM-deficient or 53BP1/p53-double-deficient pro-B cells (53, 54). However, we also observed dual IgH and Iglambda translocations in a CXc/-Pc/c tumor in which both p53 and Xrcc4 were deleted peripherally. Therefore, we must consider the alternative possibility that CXP tumors arise from peripheral B cells driven into editing. Such cells might also participate in extrafollicular responses in which CSR occurs with limited SHM (55), a possibility consistent with most CXP tumor IgH variable region exons lacking SHM.
###end p 42
###begin p 43
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 476 485 476 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH/c-myc</italic>
###xml 560 561 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 648 649 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 674 681 674 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#954;</italic>
###xml 686 694 682 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
Transitional B cell populations express very low levels of RAG upon arrival in the periphery, with RAG expression being essentially undetectable in more mature splenic B cell populations (24, 25). Thus, if the RAG breaks in CXP tumor progenitors, indeed, are generated in the periphery, it remains to be determined in what cell type they occur and how apparently low-level RAG expression could generate them. Given that CXP progenitors nearly all arise from cells that harbor IgH/c-myc translocations, it is quite striking that CXP tumors do not arise from sIg+ B cells simply in the context of aberrant CSR. Indeed, the recurrent occurrence of sIg- lymphomas with aberrant Igkappa and Iglambda rearrangements and translocations indicates that inability to productively complete receptor editing confers a major predisposition to transformation of peripheral CXP B cells. Perhaps editing CXP B cells represent a larger fraction of the CD21-expressing B cell pool than anticipated or are enriched in certain locations. For example, receptor editing might especially contribute to antibody diversification in B cells of the gut-associated lymphoid tissue (e.g., mesenteric lymph nodes), where the CXP tumors appear to arise most frequently and in which lymphocytes are chronically activated and driven into immune responses by products of the gut microflora.
###end p 43
###begin title 44
MATERIALS AND METHODS
###end title 44
###begin title 45
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 45
###begin p 46
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD21cre</italic>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">57</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 242 250 <span type="species:ncbi:9606">Children</span>
CD21cre/Xrcc4c/- mice were generated as previously described (30) and crossed into p53 germline-deficient mice (56) or mice carrying conditional p53 alleles (57). Animal work was approved by the Institutional Animal Care and Use Committee of Children's Hospital Boston.
###end p 46
###begin title 47
Southern, Northern, and Western blot.
###end title 47
###begin p 48
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 255 257 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">59</xref>
###xml 549 551 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">60</xref>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:9925">goat</span>
###xml 837 842 <span type="species:ncbi:10090">mouse</span>
###xml 881 885 <span type="species:ncbi:9925">goat</span>
###xml 891 896 <span type="species:ncbi:10090">mouse</span>
###xml 909 913 <span type="species:ncbi:9925">goat</span>
###xml 919 924 <span type="species:ncbi:10090">mouse</span>
###xml 940 944 <span type="species:ncbi:9925">goat</span>
###xml 950 955 <span type="species:ncbi:10090">mouse</span>
Genomic DNA was isolated from tumor masses or normal tissues from control mice, and Southern blotting was performed as previously described (58). 3'Jkappa probe was a 1-kb XbaI-HindIII fragment from plasmid pSPIg8 containing the Jkappa and Ckappa region (59), or generated by PCR using the following primers: 3' Jkappa5, 5'-CATCCAAGAGATTGGATCGGAGAATAAGCA-3'; MA35, 5'-AACACTGGATAAAGCAGTTTATGCCCTTTC-3'; and plasmid pSPIg8 as template. Ckappa probe was a 1.7-kb HindIII-BglII fragment covering the Ckappa region. RS probes were previously described (60). RNA samples were extracted from tumor masses or normal tissues from control mice using TriPure Isolation Reagent (Roche). Northern blotting was performed following a standard protocol. Western blotting was performed using HRP-conjugated antibodies at 1:1,000 dilution (HRP goat anti-mouse IgM [mu chain-specific antibody], HRP goat anti-mouse lambda, HRP goat anti-mouse kappa, and HRP goat anti-mouse IgG [gamma chain-specific antibody]; SouthernBiotech). Additional primers used for generating probes are detailed in the Supplemental materials and methods (available at ).
###end p 48
###begin title 49
Phage and PCR cloning.
###end title 49
###begin p 50
###xml 353 358 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 370 375 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 388 393 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
Tumor DNA samples were digested to completion with EcoRI, and fragments were cloned into either lambdaZAP II vector (Stratagene) or lambdaDASH II vector (Stratagene) according to the size of the fragments. Libraries were screened according to standard protocols (Stratagene) using Clambda1 or Jlambda2 probe for lambda rearrangements or translocations; c-myc probe A or c-myc probe D for c-myc translocations; Calpha, Cgamma1, and Sgamma1 probes for S region rearrangement and translocations (see details for probes in the Supplemental materials and methods). Single plaques were purified, subcloned, and sequenced. In the case of lambdaZAPII clones, the inserts were excised according to the protocol provided (Stratagene). Positive clones were verified by restriction analysis and hybridization. Sequencing of subcloned inserts was performed using T7 or T3 primers (DF-HCC DNA Resource Core). To obtain junctional sequences, internal primers were required for some tumors. For PCR cloning of Iglambda rearrangements: Vlambda1int:5'-ttgtgactcaggaatctgca-3' and Lamin 5'-ggagcagtctgaaatgagacaaagcat-3' were used. Additional primers used for PCR cloning of junctions are detailed in Online supplemental material.
###end p 50
###begin title 51
SKY and FISH analyses.
###end title 51
###begin p 52
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">61</xref>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242; IgH</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 349 350 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib62">62</xref>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
Preparation of metaphase chromosomes, SKY analyses, FISH, and whole-chromosome painting using single-chromosome-specific paints were performed as previously described (61). FISH probes were as follows: a BAC that covered the 3' region of the IgH locus encompassing 3' IgH enhancer and 100 kb downstream (3' IgH BAC), a BAC just upstream of the IgH VH region (5' IgH BAC) as described previously (62), and a BAC that contained the c-myc gene (RP23-307D14, c-myc BAC). BACs for Iglambda regions are RP23-382P9, RP23-60E14, RP23-374P12, and BACs for Igkappa regions are RP23-84F6 and RP23-64I9. All the BACs were obtained from BACPAC CHORI database, except for the IgH BACs.
###end p 52
###begin title 53
Online supplemental material.
###end title 53
###begin p 54
###xml 232 235 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 236 239 236 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xrcc4</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgH</italic>
###xml 722 731 703 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Igh/c-myc</italic>
###xml 787 792 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 834 839 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 969 977 950 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ig&#955;</italic>
###xml 1258 1261 1234 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1262 1265 1238 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
###xml 1419 1422 1395 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/&#8722;</sup>
###xml 1423 1426 1399 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c/c</sup>
Fig. S1 shows the FACS, Northern blot, and RT-PCR data for assays used to characterize indicated surface protein and transcript expression by CXP lymphomas. Fig. S2 shows a Kaplan-Meier curve and summary of tumors that develop in CXc/-Pc/c lymphomas. Fig. S3 shows the evidence for specific Xrcc4 deletion via CD21cre. Fig. S4 shows assays for IgH S region rearrangements in CXP lymphomas. Fig. S5 shows Southern blot data for Igkappa and Iglambda rearrangements and sequences of aberrant VlambdaJlambda joins in CXP lymphomas. Fig. S6 shows various characterizations of translocations in CXP tumors, including representative cytogenetic data (SKY, FISH, and chromosome paints) for analyses that were used to characterize Igh/c-myc translocations, Southern blots for characterization of c-myc rearrangements, Northern blot assays for c-myc expression, and sequences of translocation breakpoints. Fig. S7 displays cytogenetic data (SKY, FISH, and chromosome paints) for Iglambda translocations, and sequence data for translocation breakpoints from CXP lymphomas. Fig. S8 displays CGH array data for analysis of genetic amplifications and deletions in CXP lymphomas. Table S1 summarizes the phenotypes of CXP lymphomas. Table S2 summarizes the phenotypes of CXc/-Pc/c lymphomas. Table S3 summarizes the characterized clonal translocations in CXP lympomas. Table S4 summarizes the characterized clonal translocations in CXc/-Pc/c lymphomas. The online supplemental material is available at .
###end p 54
###begin p 55
###xml 263 268 <span type="species:ncbi:9606">Women</span>
We thank Drs. L. Chin and Y. Xiao (The Belfer Cancer Genomics Center at Dana Farber Cancer Institute, Boston MA) for analysis of CGH data; Dr. S. Casola, P. Goff, and T. Hickernell for technical assistance and suggestions; Drs. J. Kutok and J. Aster (Brigham and Women's Hospital, Boston, MA) for histology analysis; and members of the Alt laboratory for discussions.
###end p 55
###begin p 56
This work was supported by National Institutes of Health (NIH) grants 5P01 CA92625 (to F.W. Alt and K. Rajewsky), an NIH postdoctoral training grant NRSA T32 CA7008 (to C.T. Yan), Leukemia and Lymphoma Society (LLS) senior fellowships (to J.H. Wang and M. Gostissa), a LLS fellowship (to A. Datta). F.W. Alt is an investigator for the Howard Hughes Medical Institute.
###end p 56
###begin p 57
The authors have no conflicting financial interests.
###end p 57

